These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 1350939

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The development of busulfan/cyclophosphamide preparative regimens.
    Santos GW.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
    [Abstract] [Full Text] [Related]

  • 5. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
    Kalaycioglu ME, Bolwell BJ.
    Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
    Bär BM, Schattenberg A, De Man AJ, Hoogenhout MJ, Boezeman J, de Witte T.
    Bone Marrow Transplant; 1992 Jul; 10(1):45-52. PubMed ID: 1515878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide.
    Kalaycioglu M, Copelan E, Avalos B, Klein J, Goormastic M, Bolwell B.
    Bone Marrow Transplant; 1995 Jan; 15(1):105-10. PubMed ID: 7742742
    [Abstract] [Full Text] [Related]

  • 15. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I, Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos BR, Tutschka P.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [Abstract] [Full Text] [Related]

  • 16. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
    Ball ED, Wilson J, Phelps V, Neudorf S.
    Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
    [Abstract] [Full Text] [Related]

  • 17. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.
    Anderson JE, Appelbaum FR, Schoch G, Barnett T, Chauncey TR, Flowers ME, Storb R.
    Biol Blood Marrow Transplant; 2001 Apr; 7(3):163-70. PubMed ID: 11302550
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
    Van der Jagt RH, Appelbaum FR, Petersen FB, Bigelow CL, Fisher LD, Schoch GH, Buckner CD, Sanders JE, Storb R, Sullivan KM.
    Bone Marrow Transplant; 1991 Sep; 8(3):211-5. PubMed ID: 1958901
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
    Thall PF, Champlin RE, Andersson BS.
    Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.